References
- House of Lords – Science and Technology Committee. Regenerative Medicine Report, Science and Technology Committee, HL Paper 23. The Stationery Office, London, UK (2013).
- Mastroeni M , MittraJ, Tait,J. Methodology for the Analysis of Life Science Innovation Systems (ALSIS) and its Application to Three Case Studies. Innogen, Edinburgh, UK (2012)
- Knoepfler PS . Key anticipated regulatory issues for clinical use of human induced pluripotent stem cells. Regen. Med.7(5) , 713–720 (2012)
- Hauskeller C , Wilson-KovacsD. Travelling across borders: the pitfalls of clinical trial regulation and stem cell exceptionalism. Am. J. Bioeth.10 , 38–40 (2010).
- EMA – Committee for Advanced Therapies. CAT-Interested Parties (IPs) Focus Groups. A New Model for a Fruitful Interaction Between CAT and its Stakeholders, Stakeholder Workshop. EMA, London, UK (2012).
- Faulkner A . Tissue engineered technologies: regulatory pharmaceuticalization in the European Union. Innovation25(4) , 389–408 (2012).
- EMA. Assessment Report for ChondroCelect. EMA, London, UK (2009).
- The Global Dynamics of Regenerative Medicine. Webster A (Ed.). Palgrave Macmillan, Basingstoke, UK (2013).
- Ancans J . Cell-based medicinal product regulatory framework in Europe and its application to MSC-based therapy development. Front. Immunol.3(253) , 1–8 (2012).
- Biotechnology and Biological Sciences Research Council. Survey of Regenerative Medicine Activity in UK. Biotechnology and Biological Sciences Research Council, London, UK (2012).
- European Commission Health and Consumers Directorate General. European Commission Regulation EC 1394/2007 on Advanced Therapy Medicinal Products: Summary of the Responses to the Public Consultation, Health and Consumers DG. EU, Brussels, Belgium (2013).
- REMEDiE Project: Regenerative Medicine in Europe, Final Report, 2012. University of York, York, UK (2013).